Skip to main content
. 2020 May 27;12:1758835920923424. doi: 10.1177/1758835920923424

Figure 1.

Figure 1.

Survival outcomes from the start of second-line nab-P/Gem.

The median OS (A) and PFS (B) from the start of second-line nab-P/Gem therapy were 9.8 (95% CI, 8.9–10.6) and 4.6 months (3.7–5.5), respectively.

CI, confidence interval; nab-P/Gem, nab-paclitaxel and gemcitabine; OS, overall survival; PFS, progression-free survival.